EMRELIS
Live / Applied — Fourth extension granted (statement of use) (as of 29 Apr 2025)
What this means for you
Not registered yet, but its 13 Oct 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97631084
- Mark type
- Stylized text
- Filed
- 13 Oct 2022
- Published for opposition
- 14 Mar 2023
- Attorney of record
- Cheryl A. Withycombe
Goods and services
- Class 005 — Pharmaceuticals: pharmaceutical substances and preparations for the treatment of oncological diseases and disorders
Owner
- AbbVie Inc., North Chicago, IL, US
- AbbVie Inc., North Chicago, IL, US
Prosecution history
- 15 Oct 2025 — TEAS STATEMENT OF USE RECEIVED
- 30 Apr 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 29 Apr 2025 — SOU EXTENSION 4 GRANTED
- 29 Apr 2025 — SOU EXTENSION 4 FILED
- 29 Apr 2025 — SOU TEAS EXTENSION RECEIVED
- 07 Nov 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 07 Nov 2024 — SOU EXTENSION 3 GRANTED
- 07 Nov 2024 — SOU EXTENSION 3 FILED
- 07 Nov 2024 — SOU TEAS EXTENSION RECEIVED
- 10 May 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 09 May 2024 — SOU EXTENSION 2 GRANTED
- 09 May 2024 — SOU EXTENSION 2 FILED
- 09 May 2024 — SOU TEAS EXTENSION RECEIVED
- 31 Oct 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 29 Oct 2023 — SOU EXTENSION 1 GRANTED